Literature DB >> 19082487

Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches.

Sojung Lee1, Jungwoo Kang, Minchul Cho, Eunhee Seo, Heesook Choi, Eunjin Kim, Junghee Kim, Heejong Kim, Gum Yong Kang, Kwang Pyo Kim, Young-Ho Park, Dae-Yeul Yu, Young Na Yum, Sue-Nie Park, Do-Young Yoon.   

Abstract

The mutated K-ras gene is involved in approximately 30% of human cancers. In order to search for K-ras oncogene-induced modulators in lung tissues of K-ras transgenic mice, we performed microarray and proteomics (LC/ESI-MS/MS) analysis. Genes (RAB27b RAS family, IL-1RA, IL-33, chemokine ligand 6, epiregulin, EGF-like domain and cathepsin) related to cancer development (Wnt signaling pathway) and inflammation (chemokine/cytokine signaling pathway, Toll receptor signaling) were up-regulated while genes (troponin, tropomodulin 2, endothelial lipase, FGFR4, integrin alpha8 and adenylate cyclase 8) related to the tumor suppression such as p53 pathway, TGF-beta signaling pathway and cadherin signaling pathway were down-regulated by K-ras oncogene. Proteomics approach revealed that up-regulated proteins in lung adenomas of K-ras mice were classified as follows: proteins related to the metabolism/catabolism (increased from 7 to 22% by K-ras gene), proteins related to translation/transcription and nucleotide (from 4 to 6%), proteins related to signal transduction (from 3 to 5%), proteins related to phosphorylation (from 1 to 2%). ATP synthase, Ras oncogene family, cytochrome c oxidase, flavoprotein, TEF 1, adipoprotein A-1 BP, glutathione oxidase, fatty acid BP 4, diaphorase 1, MAPK4 and transgelin were up-regulated by K-ras oncogene. However, integrin alpha1, Ras-interacting protein (Rain), endothelin-converting enzyme-1d and splicing factor 3b were down-regulated. These studies suggest that genes related to cancer development and inflammation were up-regulated while genes related to the tumor suppression were down-regulated by K-ras, resulting in the tumor growth. Putative biomarkers such as cell cycle related genes (Cdc37), cancer cell adhesion (Glycam 1, integrin alpha8, integrin alphaX and Clec4n), signal transduction (Tlr2, IL-33, and Ccbp2), migration (Ccr1, Ccl6, and diaphorase 1 (Cyb5r3) and cancer development (epiregulin) can be useful for diagnosis and as prognosis markers and some of the target molecules can be applied for prevention of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19082487

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  21 in total

1.  Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.

Authors:  Y Terasawa; T Hotani; Y Katayama; M Tachibana; H Mizuguchi; F Sakurai
Journal:  Cancer Gene Ther       Date:  2015-01-30       Impact factor: 5.987

2.  Serum interleukin-33 levels in patients with gastric cancer.

Authors:  Pinghu Sun; Qiwen Ben; Shuiping Tu; Wenjie Dong; Xiaoguang Qi; Yunlin Wu
Journal:  Dig Dis Sci       Date:  2011-06-04       Impact factor: 3.199

3.  Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness.

Authors:  Raffaella Bonecchi; Benedetta Savino; Nicoletta Caronni; Giuseppe Celesti; Alberto Mantovani; Massimo Locati
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

4.  Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.

Authors:  Yongde Luo; Chaofeng Yang; Weiqin Lu; Rui Xie; Chengliu Jin; Peng Huang; Fen Wang; Wallace L McKeehan
Journal:  J Biol Chem       Date:  2010-07-23       Impact factor: 5.157

5.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

6.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Authors:  N Sunaga; K Kaira; H Imai; K Shimizu; T Nakano; D S Shames; L Girard; J Soh; M Sato; Y Iwasaki; T Ishizuka; A F Gazdar; J D Minna; M Mori
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

7.  IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer.

Authors:  Kameswaran Ravichandran; Sara Holditch; Carolyn N Brown; Qian Wang; Abdullah Ozkok; Mary C Weiser-Evans; Raphael Nemenoff; Makoto Miyazaki; Heather Thiessen-Philbrook; Chirag R Parikh; Danica Ljubanovic; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-25

8.  Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5.

Authors:  Sergiy Kostenko; Gianina Dumitriu; Ugo Moens
Journal:  J Mol Signal       Date:  2012-07-16

9.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

10.  Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth.

Authors:  Sucheta Telang; Kristin K Nelson; Deanna L Siow; Abdullah Yalcin; Joshua M Thornburg; Yoannis Imbert-Fernandez; Alden C Klarer; Hanan Farghaly; Brian F Clem; John W Eaton; Jason Chesney
Journal:  Mol Cancer       Date:  2012-08-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.